Some embodiments include a system. The system can comprise an energy source supply hub and an energy source supply appliance. The energy source supply hub can comprise a hub energy source supply system and a hub vehicle configured to transport the hub energy source supply system. Further, the hub energy source supply system can comprise a hub energy source supply subsystem configured to receive an energy source. Meanwhile, the energy source supply appliance can comprise an appliance energy source supply system and an appliance vehicle configured to transport the appliance energy source supply system. Further, the appliance energy source supply system can comprise an appliance energy source supply subsystem configured to receive the energy source from the hub energy source supply subsystem and to make available the energy source received to a receiver vehicle. Other embodiments of related systems, devices, and methods also are provided.

Disclosed herein is a constant shear continuous reactor device, comprising: an annular gas delivery tube comprising a gas inlet and a gas outlet; a first annular liquid delivery tube comprising a first liquid inlet and a first liquid outlet arranged concentrically around the annular gas delivery tube along a common axis, where the first liquid outlet is located at a downstream position relative to the gas outlet or is coterminous with the gas outlet; and an annular reactor wall tube comprising a final liquid inlet, a mixing zone section and a reactor outlet, where the annular reactor wall tube is arranged concentrically around the first annular liquid delivery tube along the common axis.

A skeletal isomerization process for isomerizing olefins is described. The process includes the steps of feeding an olefin-containing feed to a reactor at a space velocity of 1-100 hr.sup.−1 for a first period of time at a first temperature, followed by discontinuing, or stopping, the olefin-containing feed for a second period of time while maintaining the reactor at a second temperature, before resuming the flow of the olefin-containing feed for a third period of time. The methods of this disclosure increase the yield of the skeletal isomers product while reducing the production of C5+ heavy olefins. Additionally, the methods of this disclosure can be applied to feeds containing iso-olefins (for the production of linear olefins) or linear olefins (for the production of iso-olefins).

A skeletal isomerization process for isomerizing olefins is described. The process includes the steps of feeding an olefin-containing feed to a reactor having an isomerization catalyst with a small crystalline size that is less than 1 μm in all directions. The small crystalline size increases the life of the catalyst and the yield of skeletal isomer products, as well as reducing the formation of heavy C5+ olefin byproducts, as compared to processes using conventional catalyst with crystalline sizes of 1 μm or more.

This invention relates to compounds that are agonists of the muscarinic M.sub.1 and/or M.sub.4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M.sub.1 and M.sub.4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula ##STR00001##
where X.sup.1; X.sup.2; X.sup.3; X.sup.4; R.sup.1 R.sup.2 and R.sup.4 are as defined herein.

Methods for preparing the Bruton's Tyrosine Kinase (“BTK”) inhibitor compound 2-{3′-hydroxymethyl-1-methyl-5-[5-((S)-2-methyl-4-oxetan-3-yl-piperazin-1-yl)-pyridin-2-ylamino]-6-oxo-1,6-dihydro-[3,4′]bipyridinyl-2′-yl}-7,7-dimethyl-3,4,7,8-tetrahydro-2H,6H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one are provided. Methods for preparing tricyclic lactam compounds are also provided.

A method is provided for using twisted acenes, and more particularly to configurationally stable twisted acenes that are imbedded into the structure of [7]helicene at the fulcrum ring to form useable material structures. The helicene propagates its chiral nature into the acene, while acting as a locking mechanism to thermal racemization. These doubly-helical compounds are part of a new homologous series of polycyclic aromatic hydrocarbons, namely the [7]helitwistacenes. Such [7]helitwistacenes have utility as materials suitable for forming a circularly polarized organic light emitting diode (CP-OLED) for direct emission of circularly polarized (CP) light for the fabrication of high efficiency electronic displays.

The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, pharmaceutical composition comprising such compounds, and their use as menin/MLL protein/protein interaction inhibitors, useful for treating diseases such as cancer, including but not limited to leukemia, myelodysplastic syndrome (MDS), and myeloproliferative neoplasms (MPN); and diabetes.

The present invention relates to compounds that may be used in the treatment of Parkinson's disease, anxiety, emesis, obsessive compulsive disorder, autism, neuroprotection, cancer, depression or diabetes type 2.

The present invention relates to piperidine derivatives of formula (I) ##STR00001##
wherein Ar.sup.1, Ar.sup.2, R.sup.Ar1, R.sup.1, R.sup.2, and R.sup.3 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of formula (I), and especially to their use as CXCR7 receptor modulators.